NCT05891171AB598AB598-mediatedAB598-dosedzimberelimabadvanced solid tumorsGEJ cancermFOLFOX
…ity, which may potentiate enhanced antitumor immunity. ARC-25 ( NCT05891171) is an ongoing phase 1/1b first-in-human trial to evaluate the …
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT05891171 ×
NCT05891171
This funder is selected. Its supporting articles are shown below.